MLPAX
Price
$8.41
Change
+$0.15 (+1.82%)
Updated
Dec 20 closing price
SPMGX
Price
$8.23
Change
+$0.14 (+1.73%)
Updated
Dec 20 closing price
Ad is loading...

MLPAX vs SPMGX

Header iconMLPAX vs SPMGX Comparison
Open Charts MLPAX vs SPMGXBanner chart's image
Invesco SteelPath MLP Alpha A
Price$8.41
Change+$0.15 (+1.82%)
VolumeN/A
CapitalizationN/A
Invesco SteelPath MLP Alpha R
Price$8.23
Change+$0.14 (+1.73%)
VolumeN/A
CapitalizationN/A
MLPAX vs SPMGX Comparison Chart
Loading...
View a ticker or compare two or three
VS
MLPAX vs. SPMGX commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLPAX is a Buy and SPMGX is a Buy.

FUNDAMENTALS
Fundamentals
MLPAX (1.18B) and SPMGX (1.18B) have equal amount of cash in the bank . SPMGX (5.29) and MLPAX (5.19) have matching dividends . MLPAX was incepted earlier than SPMGX: MLPAX (15 years) vs SPMGX (6 years). MLPAX (32.00) and SPMGX (32.00) have comparable annual turnover. MLPAX (1000) and SPMGX (1000) have matching initial minimum investment requirements. MLPAX (39.83) and SPMGX (39.39) have marching annual gain over last year. MLPAX (118.69) and SPMGX (115.28) have equivalent 5 years return.
MLPAXSPMGXMLPAX / SPMGX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence15 years6 years-
Gain YTD38.95438.505101%
Front LoadN/AN/A-
Min. Initial Investment10001000100%
Min. Initial Investment IRAN/AN/A-
Net Assets1.18B1.18B100%
Annual Yield % from dividends5.195.2998%
Returns for 1 year39.8339.39101%
Returns for 3 years124.59122.38102%
Returns for 5 years118.69115.28103%
Returns for 10 years35.14N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PLAY27.401.20
+4.58%
Dave & Buster's Entertainment
TWLO107.931.90
+1.79%
Twilio
PLX1.760.02
+1.15%
Protalix BioTherapeutics
BRY3.79-0.01
-0.26%
Berry Corp
EVOK5.07-0.42
-7.65%
Evoke Pharma, Inc.